Literature DB >> 25325463

Increased inflammatory activity in nonobese patients with coronary artery disease and obstructive sleep apnea.

Erik Thunström1, Helena Glantz1,2, Michael Fu1, Tülay Yucel-Lindberg3, Max Petzold4, Kristin Lindberg1,3, Yüksel Peker1,2.   

Abstract

STUDY
OBJECTIVES: Obstructive sleep apnea (OSA) is common in patients with coronary artery disease (CAD). Enhanced vascular inflammation is implicated as a pathophysiologic mechanism but obesity is confounding. We aimed to address the association of OSA with inflammatory biomarkers in a nonobese cohort of revascularized patients with CAD and preserved left ventricular ejection fraction.
DESIGN: Cross-sectional analysis of baseline investigations of a randomized controlled trial.
SETTING: Clinic-based. PARTICIPANTS: There were 303 nonobese patients with CAD, of whom 213 with OSA (apnea-hypopnea index [AHI] ≥15 events/h) and 90 without OSA (AHI < 5 events/h). Obese patients with CAD and OSA (N = 105) were chosen as an additional control group.
INTERVENTIONS: None. MEASUREMENTS: Circulating levels of high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, IL-8, and tumor necrosis factor-α were assessed in relation to OSA diagnosis based on AHI ≥ 15 events/h as well as oxygen desaturation index (ODI) ≥ 5 events/h.
RESULTS: Nonobese patients with OSA had significantly higher levels of hs-CRP and IL-6 than those without OSA. The values did not differ significantly between obese and nonobese patients with OSA. In bivariate regression analysis, AHI ≥ 15 events/h was associated with all four biomarkers but not so in the multivariate model after adjustment for confounders. ODI ≥ 5 events/h was associated with hs-CRP (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.13-1.99) and IL-6 (OR 1.30; 95% CI 1.05-1.60) in multivariate analysis.
CONCLUSIONS: OSA with ODI ≥ 5 was independently associated with increased inflammatory activity in this nonobese CAD cohort. The intermittent hypoxemia, rather than the number of apneas and hypopneas, appears to be primarily associated with enhanced inflammation.
© 2015 Associated Professional Sleep Societies, LLC.

Entities:  

Keywords:  cardiovascular disease risk factors; inflammation; obstructive sleep apnea

Mesh:

Substances:

Year:  2015        PMID: 25325463      PMCID: PMC4335529          DOI: 10.5665/sleep.4510

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  37 in total

1.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Authors:  B Lindahl; H Toss; A Siegbahn; P Venge; L Wallentin
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

2.  High-sensitivity C-reactive protein methods examined.

Authors:  Snjezana Rothkrantz-Kos; Maria P J Schmitz; Otto Bekers; Paul P C A Menheere; Marja P van Dieijen-Visser
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

Review 3.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

4.  Prospective study of the association between sleep-disordered breathing and hypertension.

Authors:  P E Peppard; T Young; M Palta; J Skatrud
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

5.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; J R Gallimore; M B Pepys
Journal:  BMJ       Date:  2000-07-22

6.  Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.

Authors:  Takuya Yokoe; Kenji Minoguchi; Hirofumi Matsuo; Naruhito Oda; Hideko Minoguchi; Gen Yoshino; Tsutomu Hirano; Mitsuru Adachi
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

7.  Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing.

Authors:  Peter V Tishler; Emma K Larkin; Mark D Schluchter; Susan Redline
Journal:  JAMA       Date:  2003-05-07       Impact factor: 56.272

8.  C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity.

Authors:  Macy Mei-Sze Lui; Jamie Chung-Mei Lam; Henry Ka-Fung Mak; Aimin Xu; Clara Ooi; David Chi-Leung Lam; Judith Choi-Wo Mak; Pek Lan Khong; Mary Sau-Man Ip
Journal:  Chest       Date:  2009-02-18       Impact factor: 9.410

9.  Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.

Authors:  Jerry R Greenfield; Katherine Samaras; Arthur B Jenkins; Paul J Kelly; Tim D Spector; J Ruth Gallimore; Mark B Pepys; Lesley V Campbell
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

Review 10.  Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance.

Authors:  A N Vgontzas; E O Bixler; G P Chrousos
Journal:  J Intern Med       Date:  2003-07       Impact factor: 8.989

View more
  16 in total

1.  Obstructive Sleep Apnea in Children and Adolescents and the Risk of Major Adverse Cardiovascular Events: A Nationwide Cohort Study in Taiwan.

Authors:  Nian-Sheng Tzeng; Chi-Hsiang Chung; Hsin-An Chang; Chuan-Chia Chang; Ru-Band Lu; Hui-Wen Yeh; Wei-Shan Chiang; Yu-Chen Kao; Shan-Yueh Chang; Wu-Chien Chien
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

2.  A Randomized Crossover Trial Evaluating Continuous Positive Airway Pressure Versus Mandibular Advancement Device on Health Outcomes in Veterans With Posttraumatic Stress Disorder.

Authors:  Ali A El-Solh; Gregory G Homish; Guy Ditursi; John Lazarus; Nithin Rao; David Adamo; Thomas Kufel
Journal:  J Clin Sleep Med       Date:  2017-11-15       Impact factor: 4.062

3.  The effect of continuous positive airway pressure treatment on inflammatory parameters and periostin levels in patients with obstructive sleep apnea syndrome.

Authors:  Fatma Tosun; Cenk Babayiğit; Nursel Dikmen; Serdar Doğan; Emre Dirican
Journal:  Sleep Breath       Date:  2022-04-27       Impact factor: 2.816

Review 4.  Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats.

Authors:  Mak Adam Daulatzai
Journal:  Am J Neurodegener Dis       Date:  2016-06-01

5.  Roles of interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and treatment in obstructive sleep apnea: a meta-analysis.

Authors:  Anyuan Zhong; Xiaolu Xiong; Minhua Shi; Huajun Xu
Journal:  Sleep Breath       Date:  2015-11-13       Impact factor: 2.816

6.  Adropin and Inflammation Biomarker Levels in Male Patients With Obstructive Sleep Apnea: A Link With Glucose Metabolism and Sleep Parameters.

Authors:  Josko Bozic; Josip A Borovac; Tea Galic; Tina Ticinovic Kurir; Daniela Supe-Domic; Zoran Dogas
Journal:  J Clin Sleep Med       Date:  2018-07-15       Impact factor: 4.062

Review 7.  Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

8.  Cognitive decline among older adults: A hidden preexisting condition and its role in 'brain-at-risk' surgical patients.

Authors:  Connor T A Brenna; Beverley A Orser; Sinziana Avramescu; Andrew Fleet; Lilia Kaustov; Stephen Choi
Journal:  Brain Behav       Date:  2021-03-04       Impact factor: 2.708

Review 9.  A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease.

Authors:  Micha T Maeder; Otto D Schoch; Hans Rickli
Journal:  Vasc Health Risk Manag       Date:  2016-03-21

Review 10.  Tumor necrosis factor alpha is a promising circulating biomarker for the development of obstructive sleep apnea syndrome: a meta-analysis.

Authors:  Qingsheng Li; Xin Zheng
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.